|
|
||||||||
Institute for Med. Oncology and Hematology, Med. Clinic 5, Nürnberg City Hospital, Nürnberg, Germany
Key Words. Thrombopoietin • Human • Progenitor cells • Megakaryocytes • Lineage specificity • Maturation • Serum-free culture
Dr. Josef Birkmann, Inst. f. Med. Onkologie und Hämatologie, Med. Klinik 5, Flurstrasse 17, D-90340 Nürnberg, Germany.
The effects of recombinant thrombopoietin (TPO) alone and in combination with erythropoietin (EPO) and early-acting cytokines such as interleukin 3 (IL-3), stem cell factor (SCF) and GM-CSF on highly purified mobilized human CD34+ progenitor cells were studied in a serum-depleted culture system. Eight leukapheresis samples were cultured for seven days and analyzed; aliquots were replated and re-evaluated on day 12. Three-color flow cytometry was used together with morphologic analysis to determine proliferation and megakaryocytic or erythroid maturation.
TPO alone was sufficient for cell survival and proliferation in serum-depleted medium. In the absence of other growth factors, almost all CD34+ cells differentiated along the megakaryocytic pathway within 12 days. Concomitantly, the progenitor cells gradually acquired the morphologic features of mature megakaryocytes. After exposure to TPO for one week, 50% of the cells still expressed CD34; by day 12 the remaining CD34+ cells (11%) were all coexpressing CD41. TPO alone did not support proliferation of glycophorin-A-positive cells.
The addition of TPO to early-acting cytokines (EPO, GM-CSF, SCF and/or IL-3) not only increased the overall megakaryocyte expansion, but also generated a different maturation pattern of the CD41+ megakaryocyte progenitors. It further doubled the number of erythroid cells and c-kit+ cells in the second week of culture. Interestingly, the overall number of CD34+ cells was increased about fivefold when TPO was added to the early-acting cytokines, with a marked expansion of the CD34+/CD41+ and CD34+/CD117+ subpopulations. TPO can augment the pool of committed progenitors, thereby increasing the number of its own target cells and the number of EPO-responsive cells. These properties make TPO an interesting cytokine for the ex vivo expansion of human progenitor cells.
This article has been cited by other articles:
![]() |
T. Köhler, R. Plettig, W. Wetzstein, B. Schaffer, R. Ordemann, H.-O. Nagels, G. Ehninger, and M. Bornhäuser Defining Optimum Conditions for the Ex Vivo Expansion of Human Umbilical Cord Blood Cells. Influences of Progenitor Enrichment, Interference with Feeder Layers, Early-Acting Cytokines and Agitation of Culture Vessels Stem Cells, January 1, 1999; 17(1): 19 - 24. [Abstract] [Full Text] |
||||
![]() |
J. O. Armitage Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Blood, December 15, 1998; 92(12): 4491 - 4508. [Full Text] [PDF] |
||||
![]() |
J. P. Goff, D. S. Shields, and J. S. Greenberger Influence of Cytokines on the Growth Kinetics and Immunophenotype of Daughter Cells Resulting From the First Division of Single CD34+Thy-1+lin- Cells Blood, December 1, 1998; 92(11): 4098 - 4107. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |